<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00940342</url>
  </required_header>
  <id_info>
    <org_study_id>2004-0102</org_study_id>
    <secondary_id>NCI-2012-01670</secondary_id>
    <nct_id>NCT00940342</nct_id>
  </id_info>
  <brief_title>Rituximab Plus Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic Leukemia</brief_title>
  <official_title>Rituximab In Combination With Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic Leukemia (CLL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if giving granulocyte-macrophage
      colony-stimulating factor (GM-CSF) together with rituximab can improve the ability of
      rituximab to shrink or slow the growth of Chronic Lymphocytic Leukemia (CLL). The safety of
      this combination treatment will also be studied.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GM-CSF is a drug designed to stimulate the immune system. It will increase the number of a
      certain type of blood cell called neutrophils and macrophages.

      Rituximab is a drug designed to bind to a protein, called cluster of differentiation antigen
      20 (CD20), that is on the surface of the leukemia cells, allowing the leukemia cells to be
      destroyed by the immune system.

      Before you can start treatment on this study, you will have what are called &quot;screening
      tests&quot;. These tests will help the doctor decide if you are eligible to take part in the
      study. You will have a complete medical history and physical exam, including routine blood
      tests (about 2 tablespoons). A bone marrow aspirate will be collected. To collect a bone
      marrow aspirate, an area of the hip or chest bone is numbed with anesthetic and a small
      amount of bone marrow is withdrawn through a large needle. Imaging studies (such as a chest
      x-ray or CT scans) may be performed. Women who are able to have children must have a negative
      blood pregnancy test.

      If you are found to be eligible to take part in this study, you will receive GM-CSF as an
      injection under the skin, three times a week for eight weeks. You will receive rituximab by
      vein, once a week for four weeks. Usually, the first dose of rituximab requires several hours
      to complete. Later doses should usually be shorter, but may vary according to individual
      tolerance. Acetaminophen (Tylenol), diphenhydramine hydrochloride (Benadryl), and steroids
      (hydrocortisone or similar) will be given before rituximab to decrease the risk of side
      effects. If side effects do occur during the infusion, you will need to stay at the hospital
      and be observed until the side effects have gone away. Other than that, treatment will be
      given on an outpatient basis.

      During treatment you will have routine blood tests (about 1 tablespoon) once a week. The
      treatment will take about 8 weeks to be completed. You will be taken off study if your
      disease gets worse or if the side effects become too severe.

      After treatment is over, you will have a complete physical exam, including routine blood
      tests (about 2 tablespoons). A bone marrow sample will be taken. Imaging studies (such as a
      chest x-ray or CT scans) may be repeated to evaluate the effect of the treatment. If this
      treatment has worked for you, your doctor may advise you to receive it again for a second
      time.

      You will then return for post-treatment evaluation every 6 months for 1 year and then once a
      year for 3 years or until you start a new treatment.

      This is an investigational study. GM-CSF and rituximab have been approved by the FDA for
      clinical use. Their use together in this study, however, is experimental. Up to 130 patients
      may take part in this study. All patients will be enrolled at M.D. Anderson Cancer Center.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 12, 2004</start_date>
  <completion_date type="Actual">January 5, 2017</completion_date>
  <primary_completion_date type="Actual">January 5, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>Blood tests once a week during 8 weeks of treatment.</time_frame>
    <description>Overall Response Rate - Complete Response (CR) + Partial Response (PR). CR is the absence of Lymphocyte infiltrates on biopsy, &lt;30% Lymphocytes on Bone Marrow Aspirate, Lymphocytes &lt; 4,000ul , Hemoglobin &gt;11.0 g/dl , Platelets &gt;1000,000/ul, Polymorphonuclear neutrophils (PMN) &gt;1,500/ul, Liver/Spleen not palpable, Nodes none. PR is &lt;30% Lymphocytes with residual disease on biopsy for nodular PR, Lymphocytes &gt;50% decrease, Hemoglobin (un-transfused) &gt; 11.0 g/dl or &gt;50% improvement from baseline, Platelets &gt; 100,000/ul or 50% improvement from baseline, PMN &gt;1,500 ul or 50% improvement from baseline, Liver/Spleen &gt;/= 50% decrease, Nodes &gt;/= 50%.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Treated and Relapsed - Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive one (1) course of therapy. One course of therapy consists of four (4) doses of Rituximab 375 mg/m2, administered once weekly by vein for 4 weeks along with GM-CSF 250 mcg subcutaneously three times weekly for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treated and High-Risk for Progression - Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive one (1) course of therapy. One course of therapy consists of four (4) doses of Rituximab 375 mg/m2, administered once weekly by vein for 4 weeks along with GM-CSF 250 mcg subcutaneously three times weekly for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>70 Years of Age and Refused Chemo - Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive one (1) course of therapy. One course of therapy consists of four (4) doses of Rituximab 375 mg/m2, administered once weekly by vein for 4 weeks along with GM-CSF 250 mcg subcutaneously three times weekly for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GM-CSF (Sargramostim)</intervention_name>
    <description>250 mcg injection under the skin, three times a week for eight weeks.</description>
    <arm_group_label>70 Years of Age and Refused Chemo - Group 3</arm_group_label>
    <arm_group_label>Treated and High-Risk for Progression - Group 2</arm_group_label>
    <arm_group_label>Treated and Relapsed - Group 1</arm_group_label>
    <other_name>Sargramostim</other_name>
    <other_name>Leukine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375 mg/m^2 administered intravenously once weekly for four weeks</description>
    <arm_group_label>70 Years of Age and Refused Chemo - Group 3</arm_group_label>
    <arm_group_label>Treated and High-Risk for Progression - Group 2</arm_group_label>
    <arm_group_label>Treated and Relapsed - Group 1</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Group 1. Diagnosis of previously treated B-CLL Rai III-IV or earlier stage disease
             with evidence of &quot;active disease&quot; as defined by the NCI-sponsored working group 1)
             weight loss of &gt;10% in prior 6 months, 2) extreme fatigue, 3) fever or night sweats
             without evidence of infection, 4) worsening anemia or thrombocytopenia, 5) progressive
             lymphocytosis with a rapid lymphocyte doubling time, 6) marked hypogammaglobulinemia
             or paraproteinemia, 7) lymphadenopathy &gt;5 cm in diameter.

          2. Group 2. Diagnosis of previously untreated B-CLL with Rai stage 0-II disease but high
             risk for progression based on B2-microglobulin &gt;3.0 mg/mL, or with symptoms or
             significant fatigue.

          3. Group 3. Patients age 70 years of age and older with previously untreated B-CLL and
             Rai stage III-IV or earlier stage disease with indication for treatment who refused
             chemotherapy.

          4. Age 15 years or above.

          5. Adequate renal and hepatic functions (creatinine &lt;2.5 mg/dL, bilirubin &lt;2 mg/dL).
             Patients with renal or liver dysfunction due to organ infiltration by lymphocytes are
             eligible, as are patients with elevated bilirubin and history consistent with
             Gilbert's disease.

          6. Performance status &lt;3 (Zubrod Scale).

          7. No active viral hepatitis

        Exclusion Criteria:

        1) None.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alessandra Ferrajoli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>July 14, 2009</study_first_submitted>
  <study_first_submitted_qc>July 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2009</study_first_posted>
  <results_first_submitted>February 26, 2018</results_first_submitted>
  <results_first_submitted_qc>September 18, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 19, 2018</results_first_posted>
  <last_update_submitted>September 18, 2018</last_update_submitted>
  <last_update_submitted_qc>September 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Lymphocytic Leukemia</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Sargramostim</keyword>
  <keyword>GM-CSF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Molgramostim</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: October 2004 through January 2007. Of the 130 participants recruited, 119 participants were recruited at The University of Texas (UT) MD Anderson Cancer Center, 6 at The University of California San Diego, and 5 participants were recruited at Dana Farber Cancer Institute.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Treated and Relapsed - Group 1</title>
          <description>Participants receive one (1) course of therapy. One course of therapy consists of four (4) doses of Rituximab 375 mg/m2, administered once weekly by vein for 4 weeks along with GM-CSF 250 mcg subcutaneously three times weekly for 8 weeks.
GM-CSF (Sargramostim): 250 mcg injection under the skin, three times a week for eight weeks.
Rituximab: 375 mg/m^2 administered intravenously once weekly for four weeks</description>
        </group>
        <group group_id="P2">
          <title>Untreated and High-Risk for Progression - Group 2</title>
          <description>Participants receive one (1) course of therapy. One course of therapy consists of four (4) doses of Rituximab 375 mg/m2, administered once weekly by vein for 4 weeks along with GM-CSF 250 mcg subcutaneously three times weekly for 8 weeks.
GM-CSF (Sargramostim): 250 mcg injection under the skin, three times a week for eight weeks.
Rituximab: 375 mg/m^2 administered intravenously once weekly for four weeks</description>
        </group>
        <group group_id="P3">
          <title>70 Years of Age and Refused Chemo - Group 3</title>
          <description>Participants receive one (1) course of therapy. One course of therapy consists of four (4) doses of Rituximab 375 mg/m2, administered once weekly by vein for 4 weeks along with GM-CSF 250 mcg subcutaneously three times weekly for 8 weeks.
GM-CSF (Sargramostim): 250 mcg injection under the skin, three times a week for eight weeks.
Rituximab: 375 mg/m^2 administered intravenously once weekly for four weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treated and Relapsed - Group 1</title>
          <description>Participants receive one (1) course of therapy. One course of therapy consists of four (4) doses of Rituximab 375 mg/m2, administered once weekly by vein for 4 weeks along with GM-CSF 250 mcg subcutaneously three times weekly for 8 weeks.
GM-CSF (Sargramostim): 250 mcg injection under the skin, three times a week for eight weeks.
Rituximab: 375 mg/m^2 administered intravenously once weekly for four weeks</description>
        </group>
        <group group_id="B2">
          <title>Untreated and High-Risk for Progression - Group 2</title>
          <description>Participants receive one (1) course of therapy. One course of therapy consists of four (4) doses of Rituximab 375 mg/m2, administered once weekly by vein for 4 weeks along with GM-CSF 250 mcg subcutaneously three times weekly for 8 weeks.
GM-CSF (Sargramostim): 250 mcg injection under the skin, three times a week for eight weeks.
Rituximab: 375 mg/m^2 administered intravenously once weekly for four weeks</description>
        </group>
        <group group_id="B3">
          <title>70 Years of Age and Refused Chemo - Group 3</title>
          <description>Participants receive one (1) course of therapy. One course of therapy consists of four (4) doses of Rituximab 375 mg/m2, administered once weekly by vein for 4 weeks along with GM-CSF 250 mcg subcutaneously three times weekly for 8 weeks.
GM-CSF (Sargramostim): 250 mcg injection under the skin, three times a week for eight weeks.
Rituximab: 375 mg/m^2 administered intravenously once weekly for four weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="40"/>
            <count group_id="B4" value="130"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" lower_limit="41" upper_limit="84"/>
                    <measurement group_id="B2" value="56.5" lower_limit="34" upper_limit="70"/>
                    <measurement group_id="B3" value="73" lower_limit="70" upper_limit="83"/>
                    <measurement group_id="B4" value="69" lower_limit="34" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="123"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Response Rate</title>
        <description>Overall Response Rate - Complete Response (CR) + Partial Response (PR). CR is the absence of Lymphocyte infiltrates on biopsy, &lt;30% Lymphocytes on Bone Marrow Aspirate, Lymphocytes &lt; 4,000ul , Hemoglobin &gt;11.0 g/dl , Platelets &gt;1000,000/ul, Polymorphonuclear neutrophils (PMN) &gt;1,500/ul, Liver/Spleen not palpable, Nodes none. PR is &lt;30% Lymphocytes with residual disease on biopsy for nodular PR, Lymphocytes &gt;50% decrease, Hemoglobin (un-transfused) &gt; 11.0 g/dl or &gt;50% improvement from baseline, Platelets &gt; 100,000/ul or 50% improvement from baseline, PMN &gt;1,500 ul or 50% improvement from baseline, Liver/Spleen &gt;/= 50% decrease, Nodes &gt;/= 50%.</description>
        <time_frame>Blood tests once a week during 8 weeks of treatment.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treated and Relapsed - Group 1</title>
            <description>Participants receive one (1) course of therapy. One course of therapy consists of four (4) doses of Rituximab 375 mg/m2, administered once weekly by vein for 4 weeks along with GM-CSF 250 mcg subcutaneously three times weekly for 8 weeks.
GM-CSF (Sargramostim): 250 mcg injection under the skin, three times a week for eight weeks.
Rituximab: 375 mg/m^2 administered intravenously once weekly for four weeks</description>
          </group>
          <group group_id="O2">
            <title>Untreated and High-Risk for Progression - Group 2</title>
            <description>Participants receive one (1) course of therapy. One course of therapy consists of four (4) doses of Rituximab 375 mg/m2, administered once weekly by vein for 4 weeks along with GM-CSF 250 mcg subcutaneously three times weekly for 8 weeks.
GM-CSF (Sargramostim): 250 mcg injection under the skin, three times a week for eight weeks.
Rituximab: 375 mg/m^2 administered intravenously once weekly for four weeks</description>
          </group>
          <group group_id="O3">
            <title>70 Years of Age and Refused Chemo - Group 3</title>
            <description>Participants receive one (1) course of therapy. One course of therapy consists of four (4) doses of Rituximab 375 mg/m2, administered once weekly by vein for 4 weeks along with GM-CSF 250 mcg subcutaneously three times weekly for 8 weeks.
GM-CSF (Sargramostim): 250 mcg injection under the skin, three times a week for eight weeks.
Rituximab: 375 mg/m^2 administered intravenously once weekly for four weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate</title>
          <description>Overall Response Rate - Complete Response (CR) + Partial Response (PR). CR is the absence of Lymphocyte infiltrates on biopsy, &lt;30% Lymphocytes on Bone Marrow Aspirate, Lymphocytes &lt; 4,000ul , Hemoglobin &gt;11.0 g/dl , Platelets &gt;1000,000/ul, Polymorphonuclear neutrophils (PMN) &gt;1,500/ul, Liver/Spleen not palpable, Nodes none. PR is &lt;30% Lymphocytes with residual disease on biopsy for nodular PR, Lymphocytes &gt;50% decrease, Hemoglobin (un-transfused) &gt; 11.0 g/dl or &gt;50% improvement from baseline, Platelets &gt; 100,000/ul or 50% improvement from baseline, PMN &gt;1,500 ul or 50% improvement from baseline, Liver/Spleen &gt;/= 50% decrease, Nodes &gt;/= 50%.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events captured from the time of participant consent and will be followed to resolution or stabilization. Adverse events reported during each treatment course, up to 8 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treated and Relapsed - Group 1</title>
          <description>Participants receive one (1) course of therapy. One course of therapy consists of four (4) doses of Rituximab 375 mg/m2, administered once weekly by vein for 4 weeks along with GM-CSF 250 mcg subcutaneously three times weekly for 8 weeks.
GM-CSF (Sargramostim): 250 mcg injection under the skin, three times a week for eight weeks.
Rituximab: 375 mg/m^2 administered intravenously once weekly for four weeks</description>
        </group>
        <group group_id="E2">
          <title>Untreated and High-Risk for Progression - Group 2</title>
          <description>Participants receive one (1) course of therapy. One course of therapy consists of four (4) doses of Rituximab 375 mg/m2, administered once weekly by vein for 4 weeks along with GM-CSF 250 mcg subcutaneously three times weekly for 8 weeks.
GM-CSF (Sargramostim): 250 mcg injection under the skin, three times a week for eight weeks.
Rituximab: 375 mg/m^2 administered intravenously once weekly for four weeks</description>
        </group>
        <group group_id="E3">
          <title>70 Years of Age and Refused Chemo - Group 3</title>
          <description>Participants receive one (1) course of therapy. One course of therapy consists of four (4) doses of Rituximab 375 mg/m2, administered once weekly by vein for 4 weeks along with GM-CSF 250 mcg subcutaneously three times weekly for 8 weeks.
GM-CSF (Sargramostim): 250 mcg injection under the skin, three times a week for eight weeks.
Rituximab: 375 mg/m^2 administered intravenously once weekly for four weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Neutropenic Fever</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Ischemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="50"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Shortness of Breath</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Injection Site Reaction</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alessandra Ferrajoli, MD/Professor</name_or_title>
      <organization>The University of Texas MD Anderson Cancer Center</organization>
      <phone>713-792-7734</phone>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

